Abstracts tagged "pregnancy"

Abstract Number: 2395 • ACR Convergence 2025
Analysis of histopathological changes in the placenta of patients with systemic lupus erythematosus
Bartira Melo¹, Elizabeth Avvad², Marcela lacerda², Nilson jesus², Evandro Klumb² and Guilherme Ramires de Jesus³, ¹UERJ- Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²UERJ - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is more frequent in women of reproductive age and pregnancy in these patients is considered as high risk. The inflammatory…
Abstract Number: 2208 • ACR Convergence 2025
Contraception and Pregnancy Experiences of Veterans from Minoritized Populations with Rheumatoid Arthritis
Catherine Sims¹, Yujung Choi², Abigail Shapiro³, Elizabeth Strawbridge², Jennifer Gierisch¹, Teresa Howard², Ankoor Shah¹ and Karen Goldstein¹, ¹VA Durham Healthcare System, Duke University, Durham, ²VA Durham Healthcare System, Durham, ³VA Durham Healthcare System, Cleveland
Background/Purpose: More than 8,500 women Veterans carry a diagnosis of rheumatoid arthritis (RA), however, there are limited data on the reproductive health and experiences of…
Abstract Number: 0933 • ACR Convergence 2025
Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Yunwei Xia¹, Paul Hoover², Arnon Arazi³ and Anne Davidson¹, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Brigham and Women's Hospital, Boston, MA, ³Feinstein Institutes for Medical Research, Acton, MA
Background/Purpose: TLR8 has been implicated in adverse outcomes of human pregnancy. We previously reported a mouse model of spontaneous aPL-induced pregnancy loss in Sle1 mice…
Abstract Number: 2225 • ACR Convergence 2025
The Impact of Pregnancy Planning on the Prevalence of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Retrospective Study from Three Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², YORIKAZU HASHIMOTO³, Eri Soga⁴, Sho Fukui⁵, Ayako Kitada⁶, Kensuke Nakanishi⁷, Naoto Yokogawa⁸ and Masato Okada⁹, ¹Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Matsuzawa hospital, Setagaya-ku, Tokyo, Japan, ³Nanbu Medical Center & Children's Medical Center, Naha, Japan, ⁴Tokyo Metropolitan Tama Medical Center, Tama, Tokyo, Japan, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ⁶St Luke's International hospital, nagareyama-shi, chiba- ken, Japan, ⁷Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Haebaru, Okinawa, Japan, ⁸Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Tokyo, Japan, ⁹St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with a higher risk of adverse pregnancy outcomes (APOs) compared to the general population. Although several APO risk…
Abstract Number: 2206 • ACR Convergence 2025
Adolescents with Systemic Lupus Erythematosus at Highest Risk of Adverse Pregnancy Outcomes
Catherine Deffendall¹, Sarah Green², Ashley Suh², Bryan Han² and April Barnado², ¹Vanderbilt University, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Few studies exist that examine pregnancy outcomes in adolescents with SLE. To our knowledge, there have been no studies comparing SLE adolescent pregnancies to…
Abstract Number: 0626 • ACR Convergence 2025
Evaluation of Novel Anti-ATP1A1 Autoantibodies by ELISA to Predict Cardiac Neonatal Lupus (Cardiac-NL)
Nalani Sachan¹, Philip Carlucci², Mala Masson³, Nicola Fraser¹, Peter Izmirly⁴, Camila Hernández-Blanco⁵, Robert Clancy⁶, Bettina Cuneo⁷ and Jill Buyon¹, ¹NYU Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶Columbia University, New York, NY, ⁷University of Arizona College of Medicine, Tucson, AZ
Background/Purpose: For childbearing women with SLE and other autoimmune diseases, the nearly invariant association of cardiac-NL with maternal SSA/Ro52/60kD autoantibodies supports the necessity of these…
Abstract Number: 2224 • ACR Convergence 2025
Failure of Steroid and Antimalarial Therapy to Normalize Placental Interferon and Angiogenic Gene Expression in SLE
Seemal Faisal¹, Alexandra Anderson², Luke Sharrock³, James Tran⁴ and Milena Vukelic⁵, ¹Louisiana State University Health Science Center New Orleans, New Orleans, ²Louisiana State University Health Science Center New Orleans, Phoenix, AZ, ³Louisiana State University Health Science Center, New Orleans, LA, ⁴Louisiana State University Health Science Center, New Orleans, ⁵Rheumatology Fellowship Program Director Louisiana State University, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with an increased risk of placental insufficiency and adverse pregnancy outcomes, even when the disease is clinically quiescent.…
Abstract Number: 2205 • ACR Convergence 2025
Effectiveness of Reproductive Health Counseling for Rheumatology Patients
Caroline Maretz¹, Daniele Marcy², Kristin Sturm³, JoAnn Zell³ and Kristen Demoruelle⁴, ¹University of Colorado Anschutz Medical Campus, Denver, CO, ²University of Colorado, Northglenn, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Golden, CO
Background/Purpose: Systemic autoimmune diseases are often treated with medications that have known teratogenic effects or unknown safety profiles in pregnancy. As these diseases frequently affect…
Abstract Number: 0610 • ACR Convergence 2025
The Role of Active Nephritis, Compared to Active Non-Renal SLE, in Pregnancy Outcomes
Emma Trachman¹, Amanda Eudy² and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: The ACR recommends against pregnancy in patients with SLE with high disease activity. These recommendations do not distinguish between the various manifestations of active…
Abstract Number: 0361 • ACR Convergence 2024
Maternal and Fetal Outcomes in Those with Autoimmune Connective Tissue Disease
Nada Alrifai¹, Anushree Puttur², Laith Alhuneafat³, Fares Ghanem⁴, yadhu Dhital², Ahmad Jabri⁵ and David Feinstein⁶, ¹Cooper University Hospital, Cherry Hill, NJ, ²Allegheny Health Network, Pittsburgh, PA, ³University of Minnesota, Minneapolis, MN, ⁴Southern Illinois University, Springfield, IL, ⁵Henry Ford, Detroit, MI, ⁶Cooper University, Camden, NJ
Background/Purpose: Autoimmune connective tissue diseases (CTD) predominantly affect women during their reproductive years. CTDs such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic…
Abstract Number: 0440 • ACR Convergence 2024
Pregnancy Outcome Disparities Among Women with Systemic Lupus Erythematosus
Jessica English¹, Bethany Wolf² and Diane Kamen², ¹Medical University of South Carolina, Johns Island, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Women with systemic lupus erythematosus (SLE) have increased rates of pre-term birth, small for gestational age babies, and pre-eclampsia compared to women without a…
Abstract Number: 0807 • ACR Convergence 2024
Evaluating Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus (SLE) and SLE Subgroups: Additional Risks Associated with Cardiovascular Events
Rashmi Dhital¹, Rebecca Baer², Kenneth Kalunian³ and Christina Chambers⁴, ¹UC San Diego, Brentwood, TN, ²UC San Diego, San Diego, ³University of California San Diego, La Jolla, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) presents substantial risks for both maternal cardiovascular events (CVEs) and adverse pregnancy outcomes, yet, the influence of maternal CVEs on…
Abstract Number: 2400 • ACR Convergence 2024
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts
Melissa Fazzari¹, Jane Salmon², Marta Guerra², Nathalie Costedoat-Chalumeau³, Veronique LE GUERN⁴, Gaëlle Guettrot-Imbert⁴, Marta Mosca⁵, Dina Zucchi⁶, Chiara Tani⁷, Rebecca Fischer-Betz⁸, Isabell Haase⁹, Anna Broder¹⁰, Navneet Kaur¹¹, Jill Buyon¹², Brooke Cohen¹², Diane Kamen¹³, Jessica English¹⁴, Anna Arar¹³ and Mimi Kim¹⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²Hospital for Special Surgery, New York, NY, ³Inserm DR Paris 5, Paris, France, ⁴Cochin hospital, Paris, France, ⁵University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ⁶Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁷University of Pisa, Pisa, Italy, ⁸Uniklinik Düsseldorf, Düsseldorf, Germany, ⁹Heinrich-Heine University Duesseldorf, Düsseldorf, Germany, ¹⁰Hackensack Network, Hackensack, NJ, ¹¹Touro University Medical Group, Sacramento, CA, ¹²NYU Grossman School of Medicine, New York, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴Medical University of South Carolina, Johns Island, SC, ¹⁵Albert Einstein College of Medicine, Larchmont, NY
Background/Purpose: Nearly 20% of pregnancies in systemic lupus erythematosus (SLE) patients result in an adverse pregnancy outcome (APO); early identification of those at high APO…
Abstract Number: 0417 • ACR Convergence 2024
Contraception in Community Rheumatology Practices
Megan Clowse¹, Julie Chiesa², Pamela Freeman³, Bansari Gujar⁴, Kelley Jones⁵, Richard Jones⁶, Ann Marslett⁷, Amanda Snyderman⁵ and Leah Zulig⁸, ¹Duke University, Chapel Hill, NC, ²InfoDirectors, Durham, NC, ³Rheumatology Associates of Central Florida, Orlando, FL, ⁴Rheumatology Associates of Baltimore, Towson, MD, ⁵Duke University School of Medicine, Durham, ⁶Clinic for Rheumatic Diseases, Northport, AL, ⁷Rheumatology Associates of Baltimore, Baltimore, MD, ⁸Duke University School of Medicine, Durham, NC
Background/Purpose: Most prior studies of contraception in women with rheumatic disease focused on academic centers. In this study of non-academic rheumatology practices, we sought to…
Abstract Number: 0441 • ACR Convergence 2024
A Qualitative Improvement Project to Incorporate the Mycophenolate Risk Evaluation and Mitigation Strategies in an Academic Lupus Clinic
Dahima Cintron¹, Jennifer Rogers², Rebecca Sadun¹, Mithu Maheswaranathan³, Kai Sun¹, Jayanth Doss¹, Lisa Criscione-Schreiber³ and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke, Durham, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Mycophenolate Mofetil/Mycophenolic acid (MMF) is an immunosuppressant used to treat SLE. Due to the teratogenic effects of MMF, the FDA recommended universal risk evaluation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].